Eugene Brown Jr. Named Among the 2025 Lawdragon 500 Leading Litigators in America
Press Release | 1 min read
Sep 10, 2024
The law firm of Hinshaw & Culbertson LLP is pleased to announce that San Francisco partner Eugene Brown Jr. has been named to Lawdragon’s 2025 guide of 500 Leading Litigators in America.
Lawdragon is a legal media company that provides online news and editorial features—including guides to the nation’s leading lawyers. Brown has previously been recognized on Lawdragon’s 500 Leading Lawyers in America list from 2020 – 2023 and was also selected to the Lawdragon 2023 Hall of Fame class.
Brown is a partner in Hinshaw's product liability practice group and has successfully tried over 125 jury trials to verdict. He has served as lead counsel in various cases, including those involving intellectual property in the Eastern District of Texas, as well as the defense of product liability, toxic tort, and complex commercial and personal injury actions across all major judicial jurisdictions in California.
Additionally, Brown holds Diplomate status as a Fellow of the American Board of Trial Advocates (ABOTA) and is a Fellow of the International Academy of Trial Lawyers (IATL), the American College of Trial Lawyers (ACTL), and the Litigation Counsel of America (LCA).
Featured Insights

Webinar
Oct 29, 2026
Carol Rooney Presents on Building a Career in Appellate Practice

In The News
Oct 28, 2026
James Ferrara Comments in The New York Times on Stalled Boca Raton Luxury Condo Project

Insights for Insurers Alert
Oct 28, 2026
Insurance and Reinsurance Commutations, Run-Off, and Loss Portfolio Transfers

Healthcare Alert
Oct 27, 2026
Illinois Medical Aid-in-Dying Law Takes Effect Amid Legal Challenges

In The News
Oct 26, 2026
Scott Seaman Examines the Insurance Coverage Implications of a Recent NFL Concussion Ruling

In The News
Oct 23, 2026
Michael Dowell Discusses Potential Impact of Proposition 44 on California Community Clinics

In The News
Oct 21, 2026
Scott Seaman Says Walmart Ruling is an "Aberration" in the Opioid Insurance Battle






